28342789|t|Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion
28342789|a|Due to the instability of esomeprazole magnesium dihydrate (EPM), a proton pump inhibitor, in gastric fluid, enteric-coated dosage form is commonly used for therapeutic application. In this study, we prepared new gastric fluid resistant solid dispersions (SDs) containing alkalizers. Then, new mechanistic evidence regarding the effects of pharmaceutical alkalizers on the aqueous stability of EPM in simulated gastric fluid was investigated. The alkalizer -loaded SD were prepared by dissolving or dispersing EPM, hydroxypropyl methylcellulose (HPMC) 6 cps, and an alkalizer, in ethanol 50% (v/v) followed by spray drying. Nine different alkalizer s were assessed for in vitro stability in two media, simulated gastric fluid (pH 1.2 buffer) and simulated intestinal fluid (pH 6.8 buffer). The microenvironmental pH (pHM) was measured to evaluate the effect of the alkalizer on the pHM of SDs. Drug crystallinity and morphology of the SDs were also examined by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), and scanning electron microscopy (SEM). The interactions among EPM, the polymer, and the alkalizer were elucidated by Fourier transform infrared (FTIR) spectroscopy. The in vivo absorption studies of the optimized alkalizer -containing SD and the enteric-coated reference tablet Nexium (®) were then conducted in beagle dogs. Among alkalizer s, MgO loaded in SDs proved to be the best alkalizer to stabilize EPM in simulated gastric fluid. pHM values of the alkalizer -containing SDs were significantly higher than that of the SD without alkalizer. The pHM values decreased in the following order: MgO, Na2CO3, Ca(OH)2, and no alkalizer. DSC and PXRD data exhibited a change in the drug crystallinity of the SDs from crystalline to amorphous form. SEM data showed a relatively spherical shape of the MgO -loaded SD compared to the less-defined shape of pure drug. FTIR indicated a strong molecular interaction among EPM, alkalizer and polymer; in particular, MgO showed the strongest interaction with EPM. It was evident that alkalizer interacts with benzimidazole ring and/or sulfonyl group of EPM for enhancing EPM stability in gastric fluid. Regarding the in vivo absorption studies in beagle dogs, the optimized SD (C16) was bioequivalent to the reference Nexium (®) and had a considerable greater absorption at the early stages. The current alkalizer -containing SD could provide a promising approach for aqueous stabilization of acid - labile drugs without using enteric coating method.
28342789	9	16	gastric	T080	C1704242
28342789	17	26	stability	T080	C0013210
28342789	30	42	esomeprazole	T109,T121	C0937846
28342789	46	67	molecular interaction	T044	C1167622
28342789	72	82	modulation	T078	C1515926
28342789	86	104	microenvironmental	T070	C3179020
28342789	105	107	pH	T081	C0020283
28342789	113	123	alkalizers	T121	C0304463
28342789	127	143	solid dispersion	T122	C3859614
28342789	155	166	instability	T033	C0443343
28342789	170	202	esomeprazole magnesium dihydrate	T109,T121	C3883231
28342789	204	207	EPM	T109,T121	C3883231
28342789	212	233	proton pump inhibitor	T121	C0358591
28342789	238	251	gastric fluid	T031	C2828094
28342789	253	274	enteric-coated dosage	T122	C0039226
28342789	301	324	therapeutic application	T061	C0087111
28342789	334	339	study	T062	C2603343
28342789	357	370	gastric fluid	T031	C2828094
28342789	381	398	solid dispersions	T122	C3859614
28342789	400	403	SDs	T122	C3859614
28342789	416	426	alkalizers	T121	C0304463
28342789	484	498	pharmaceutical	T121	C0013227
28342789	499	509	alkalizers	T121	C0304463
28342789	517	524	aqueous	T080	C0599956
28342789	525	534	stability	T080	C0013210
28342789	538	541	EPM	T109,T121	C3883231
28342789	555	568	gastric fluid	T031	C2828094
28342789	591	600	alkalizer	T121	C0304463
28342789	609	611	SD	T122	C3859614
28342789	654	657	EPM	T109,T121	C3883231
28342789	659	688	hydroxypropyl methylcellulose	T109,T121	C0063242
28342789	690	694	HPMC	T109,T121	C0063242
28342789	710	719	alkalizer	T121	C0304463
28342789	724	731	ethanol	T109,T121	C0001962
28342789	754	766	spray drying	T059	C3827958
28342789	783	792	alkalizer	T121	C0304463
28342789	813	821	in vitro	T080	C1533691
28342789	822	831	stability	T080	C0013210
28342789	856	869	gastric fluid	T031	C2828094
28342789	871	873	pH	T081	C0020283
28342789	878	884	buffer	T121,T130	C0006353
28342789	900	916	intestinal fluid	T033	C3670910
28342789	918	920	pH	T081	C0020283
28342789	925	931	buffer	T121,T130	C0006353
28342789	938	956	microenvironmental	T070	C3179020
28342789	957	959	pH	T081	C0020283
28342789	961	964	pHM	T081	C0020283
28342789	1009	1018	alkalizer	T121	C0304463
28342789	1026	1029	pHM	T081	C0020283
28342789	1033	1036	SDs	T122	C3859614
28342789	1043	1056	crystallinity	T104	C0444626
28342789	1061	1071	morphology	T080	C0332437
28342789	1079	1082	SDs	T122	C3859614
28342789	1105	1138	differential scanning calorimetry	T059	C0006780
28342789	1140	1143	DSC	T059	C0006780
28342789	1146	1170	powder X-ray diffraction	T059	C0043301
28342789	1172	1176	PXRD	T059	C0043301
28342789	1183	1211	scanning electron microscopy	T059	C0026020
28342789	1213	1216	SEM	T059	C0026020
28342789	1223	1235	interactions	T169	C1704675
28342789	1242	1245	EPM	T109,T121	C3883231
28342789	1251	1258	polymer	T109,T121	C0063242
28342789	1268	1277	alkalizer	T121	C0304463
28342789	1297	1343	Fourier transform infrared (FTIR) spectroscopy	T062	C0206055
28342789	1349	1356	in vivo	T082	C1515655
28342789	1357	1367	absorption	T067	C2347023
28342789	1368	1375	studies	T062	C2603343
28342789	1393	1402	alkalizer	T121	C0304463
28342789	1415	1417	SD	T122	C3859614
28342789	1426	1440	enteric-coated	T122	C0039226
28342789	1451	1457	tablet	T121	C0013227
28342789	1458	1464	Nexium	T109,T121	C0939400
28342789	1492	1503	beagle dogs	T015	C0324306
28342789	1511	1520	alkalizer	T121	C0304463
28342789	1524	1527	MgO	T121,T197	C0024477
28342789	1538	1541	SDs	T122	C3859614
28342789	1564	1573	alkalizer	T121	C0304463
28342789	1587	1590	EPM	T109,T121	C3883231
28342789	1604	1617	gastric fluid	T031	C2828094
28342789	1619	1622	pHM	T081	C0020283
28342789	1637	1646	alkalizer	T121	C0304463
28342789	1659	1662	SDs	T122	C3859614
28342789	1706	1708	SD	T122	C3859614
28342789	1717	1726	alkalizer	T121	C0304463
28342789	1732	1735	pHM	T081	C0020283
28342789	1777	1780	MgO	T121,T197	C0024477
28342789	1782	1788	Na2CO3	T109,T121	C0074732
28342789	1790	1797	Ca(OH)2	T121,T197	C0006701
28342789	1803	1805	no	T080	C0332288
28342789	1806	1815	alkalizer	T121	C0304463
28342789	1817	1820	DSC	T059	C0006780
28342789	1825	1829	PXRD	T059	C0043301
28342789	1861	1865	drug	T121	C0013227
28342789	1866	1879	crystallinity	T104	C0444626
28342789	1887	1890	SDs	T122	C3859614
28342789	1896	1907	crystalline	T104	C0444626
28342789	1911	1920	amorphous	T080	C1979848
28342789	1927	1930	SEM	T059	C0026020
28342789	1956	1971	spherical shape	T082	C0332501
28342789	1979	1982	MgO	T121,T197	C0024477
28342789	1991	1993	SD	T122	C3859614
28342789	2010	2022	less-defined	T080	C1518423
28342789	2023	2028	shape	T082	C0332479
28342789	2037	2041	drug	T121	C0013227
28342789	2043	2047	FTIR	T062	C0206055
28342789	2067	2088	molecular interaction	T044	C1167622
28342789	2095	2098	EPM	T109,T121	C3883231
28342789	2100	2109	alkalizer	T121	C0304463
28342789	2114	2121	polymer	T109,T121	C0063242
28342789	2138	2141	MgO	T121,T197	C0024477
28342789	2163	2174	interaction	T169	C1704675
28342789	2180	2183	EPM	T109,T121	C3883231
28342789	2205	2214	alkalizer	T121	C0304463
28342789	2215	2224	interacts	T169	C1704675
28342789	2230	2248	benzimidazole ring	T104	C1254350
28342789	2256	2270	sulfonyl group	T104	C1254350
28342789	2274	2277	EPM	T109,T121	C3883231
28342789	2292	2295	EPM	T109,T121	C3883231
28342789	2296	2305	stability	T080	C0013210
28342789	2309	2322	gastric fluid	T031	C2828094
28342789	2338	2345	in vivo	T082	C1515655
28342789	2346	2356	absorption	T067	C2347023
28342789	2357	2364	studies	T062	C2603343
28342789	2368	2379	beagle dogs	T015	C0324306
28342789	2395	2397	SD	T122	C3859614
28342789	2439	2445	Nexium	T109,T121	C0939400
28342789	2481	2491	absorption	T067	C2347023
28342789	2499	2511	early stages	T079	C2363430
28342789	2525	2534	alkalizer	T121	C0304463
28342789	2547	2549	SD	T122	C3859614
28342789	2589	2596	aqueous	T080	C0599956
28342789	2597	2610	stabilization	T080	C0013210
28342789	2614	2618	acid	T103	C0001128
28342789	2621	2627	labile	T033	C0443343
28342789	2628	2633	drugs	T121	C0013227
28342789	2634	2641	without	T080	C0332288
28342789	2648	2663	enteric coating	T122	C0039226